- Home
- MXCT vs ELDN Comparison
MXCT vs ELDN Comparison
Compare MXCT & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MXCT
- ELDN
- Stock Information
- Founded
- MXCT 1999
- ELDN 2004
- Country
- MXCT United States
- ELDN United States
- Employees
- MXCT N/A
- ELDN N/A
- Industry
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- MXCT Health Care
- ELDN Health Care
- Exchange
- MXCT Nasdaq
- ELDN Nasdaq
- Market Cap
- MXCT 159.9M
- ELDN 164.1M
- IPO Year
- MXCT 2021
- ELDN N/A
- Fundamental
- Price
- MXCT $1.67
- ELDN $4.03
- Analyst Decision
- MXCT Buy
- ELDN Strong Buy
- Analyst Count
- MXCT 4
- ELDN 2
- Target Price
- MXCT $7.50
- ELDN $12.50
- AVG Volume (30 Days)
- MXCT 561.6K
- ELDN 1.8M
- Earning Date
- MXCT 11-12-2025
- ELDN 11-12-2025
- Dividend Yield
- MXCT N/A
- ELDN N/A
- EPS Growth
- MXCT N/A
- ELDN N/A
- EPS
- MXCT N/A
- ELDN 0.21
- Revenue
- MXCT $35,754,000.00
- ELDN N/A
- Revenue This Year
- MXCT N/A
- ELDN N/A
- Revenue Next Year
- MXCT $14.72
- ELDN N/A
- P/E Ratio
- MXCT N/A
- ELDN $19.00
- Revenue Growth
- MXCT N/A
- ELDN N/A
- 52 Week Low
- MXCT $1.26
- ELDN $2.32
- 52 Week High
- MXCT $5.20
- ELDN $5.40
- Technical
- Relative Strength Index (RSI)
- MXCT 54.49
- ELDN 65.78
- Support Level
- MXCT $1.45
- ELDN $3.18
- Resistance Level
- MXCT $1.57
- ELDN $4.60
- Average True Range (ATR)
- MXCT 0.11
- ELDN 0.40
- MACD
- MXCT -0.00
- ELDN 0.05
- Stochastic Oscillator
- MXCT 71.40
- ELDN 67.05
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.